[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07568470":3,"trial-entities:NCT07568470":80,"trial-summary:NCT07568470":84},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":26,"interventions":29,"primary_outcomes":35,"secondary_outcomes":48,"sex":49,"minimum_age":50,"maximum_age":50,"healthy_volunteers":15,"eligibility_criteria":51,"std_ages":59,"locations":63,"central_contacts":72,"overall_officials":73,"references":78,"see_also_links":79},"NCT07568470","USNC","Can the Phoenix Sign be Elicited With D5W","Elicitation of the Phoenix Sign With Non-guided Subcutaneous D5W Infiltration","ENROLLING_BY_INVITATION","2027-01-15","2026-04","2026-05-05","2026-04-10","US Neuropathy Centers","OTHER",false,"To determine if the Phoenix sign can be reliably elicited with non-guided subcutaneous infiltration of D5W (5% Dextrose in Water) in patients with subclinical weakness of the extensor hallucis longus (EHL) muscle.","* To determine the prevalence of subclinical EHL weakness in a general clinical population\n* To measure the time course of strength changes following D5W infiltration\n* To identify potential predictive factors for positive response to treatment",[19],"Drop Foot",[21],"Drop Foot, Nerve Blocks","INTERVENTIONAL","DIAGNOSTIC",[25],"NA",{"count":27,"type":28},600,"ESTIMATED",[30],{"type":31,"name":32,"description":33,"armGroupLabels":34},"DRUG","Infiltration of D5W","There is no other intervention.",[32],[36,40,44],{"measure":37,"description":38,"timeFrame":39},"Changes in motor strength of dorsiflexion of the anterior and lateral compartments of the lower extremity","Each subject will receive the infiltration and then be assessed for any changes in motor strength at 4 and 10 minutes after the injection.","From enrollment to end of their treatment at 1 day",{"measure":41,"description":42,"timeFrame":43},"Presence of absence of increase in motor strength of the lower extremity in dorsiflexion","Using manual motor testing the strength of the lower extremity in dorsiflexion will be evaluated with a score of 1-5 out of 5.","From enrollment to the end of the day",{"measure":45,"description":46,"timeFrame":47},"Number of subjects that have increased dorsiflexion strength after D5W infiltration","Subjects will be evaluated by manual motor testing of the patient before and after infiltration of D5W on a 1 to 5 out of 5 mother strength grading.","Enrollment to end of clinic vist in 1 hour",[],"ALL",null,{"inclusion":52,"exclusion":55,"raw_text":58},[53,54],"subjects must have a weakness of dorsiflexion and specifically of the Extensor Hallucis Longus muscle","drop foot",[56,57],"Trypanaphobia","allergy to D5W","Inclusion Criteria:\n\n* subjects must have a weakness of dorsiflexion and specifically of the Extensor Hallucis Longus muscle\n* drop foot\n\nExclusion Criteria:\n\n* Trypanaphobia\n* allergy to D5W",[60,61,62],"CHILD","ADULT","OLDER_ADULT",[64],{"facility":13,"city":65,"state":66,"zip":67,"country":68,"geoPoint":69},"Marietta","Georgia","30067","United States",{"lat":70,"lon":71},33.9526,-84.54993,[],[74],{"name":75,"affiliation":76,"role":77},"Stephen L Barrett, DPM MBA","US Neuropathy Centers LLC","PRINCIPAL_INVESTIGATOR",[],[],{"nct_id":4,"conditions":81,"biomarkers":83},[82],"Foot-drop",[],{"nct_id":4,"found":15,"summary":50,"prompt_version":50}]